News
Videos
Conferences
Events
Resources
Subscribe

|Articles|October 1, 2014

Dana-Farber Leads Kadcyla ATEMPT Study in HER2-Positive Breast Cancer

Experts review an innovative study, called the ATEMPT study, which looks at adjuvant T-DM1 in women with HER2-positive breast cancer.

Experts review an innovative study, called the ATEMPT study, which looks at adjuvant T-DM1 in women with HER2-positive breast cancer.

Newsletter

Stay up to date on cancer updates, research and education

Related Content

Image of man.

How Monitoring Supports Survivorship After Cancer Treatment Care

ByDr. Elias Obeid

February 5th 2026

Dr. Suneel Kamath emphasized the growing importance of understanding biomarkers in patients with gastrointestinal cancers.

Expert Insights into Advances in Gastrointestinal Cancer Treatment

ByDr. Suneel Kamath

February 5th 2026

image of man.

Biomarker-Free Relacorilant Combo Broadens Options in Ovarian Cancer

ByDr. Alexander B. Olawaiye

February 5th 2026

Image of woman,

Pastina Bean Soup Supports Nutrition in Colorectal Cancer Care

BySpencer Feldman

February 4th 2026

World Cancer Day highlights the global impact of cancer, raising awareness, fostering unity and reminding us to support survivors and patients together: © stock.adobe.com.

Why World Cancer Day Matters to Patients and Survivors

ByFred Batchelor

February 4th 2026

Trending on CURE

FDA Updates Safety Warnings for Common Chemotherapy Drugs

Real-World Data with Amtagvi Show High Response Rates in Advanced Melanoma

Chemo Brain is Real: My Experience with a Clinical Study and What It Can Teach Us

New Combination Treatment Approach Studied in Pancreatic Cancer

FDA Removes Use Limitation for Yescarta in Primary CNS Lymphoma